MLAB — Mesa Laboratories Balance Sheet
0.000.00%
- $749.83m
- $859.03m
- $249.13m
Annual balance sheet for Mesa Laboratories, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 49.3 | 32.9 | 28.2 | 27.3 | 26.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 41.2 | 42.6 | 39.1 | 42 | 44.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 124 | 119 | 109 | 103 | 106 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 38.8 | 36.8 | 41.4 | 48.7 | 48.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 707 | 662 | 447 | 433 | 428 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 48.1 | 43.4 | 44.3 | 164 | 61.9 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 314 | 268 | 301 | 274 | 242 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 394 | 393 | 145 | 160 | 186 |
| Total Liabilities & Shareholders' Equity | 707 | 662 | 447 | 433 | 428 |
| Total Common Shares Outstanding |